Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Studied in peopleStub

Tesofensine

Monoamine reuptake inhibitor (not a peptide)

A small molecule that blocks the reuptake of noradrenaline, dopamine and serotonin, studied in obesity trials. It is not a peptide.

Reconstitution calculator

At a glance

Studied in people

There are published studies in people. It is not a licensed medicine in the United States or the European Union.

This page is a stub

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

How strong is the evidence

How far it has climbed

Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.

  1. Licensed medicine

    A regulator has reviewed the trials and licensed it for a named use.

  2. Phase 3

    Large randomized trials, often thousands of people, against placebo or a standard treatment.

  3. Phase 2

    Mid-sized trials that measure dose against effect in people with the condition.

  4. Phase 1 and early human studies: Tesofensine

    First studies in people: safety, and how the body handles it.

  5. Cells and animals

    Laboratory and animal work. An animal result is not a result in people.

52
papers on PubMed
40
of them in people
11
randomized trials
17
reviews

A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16

Handling and reconstitution

From powder to a measured sample

The same four steps for any lyophilized vial. Laboratory handling, not use in a person.

  1. 1. Read the vial

    The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.

  2. 2. Add the diluent

    A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.

  3. 3. Work out the strength

    Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.

  4. 4. Measure the sample

    Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.

The calculator below does the arithmetic and shows its working.

As powder

General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.

In solution

Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.

This is general practice for lyophilized peptides, not data on Tesofensine itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage

Reconstitution calculator

Opens on vial sizes common for research peptides. Change any number. How the arithmetic works

Draw to

10 units

0.1 mL on a U-100 syringe

Concentration
2.5 mg/mL
Each unit holds
25 mcg
Samples in the vial
20
Sample
250 mcg

5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Tesofensine; no amount here is a recommendation.

Tesofensine: on PubMed

What PubMed held for Tesofensine on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

52
papers
40
in humans
11
clinical trials
11
randomized trials
2012: 3 papers122013: 7 papers2014: 3 papers142015: 1 papers2016: 1 papers162017: 0 papers2018: 2 papers182019: 1 papers2020: 2 papers202021: 0 papers2022: 1 papers222023: 0 papers2024: 1 papers242025: 2 papers2026: 1 papers so far26
Papers per year, 2012 to 2026. The most in one year: 7.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. [The effect of tesofensine on body weight and body composition in obese subjects--secondary publication]

    Randomized trialNielsen AL, Larsen TM, Madsbad S, et al. Ugeskrift for laeger, 2009. PMID 19824222

  2. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity

    Randomized trialHuynh K, Klose M, Krogsgaard K, et al. European journal of endocrinology, 2022. PMID 35294397

  3. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users

    Randomized trialSchoedel KA, Meier D, Chakraborty B, et al. Clinical pharmacology and therapeutics, 2010. PMID 20520602

  4. The effect of tesofensine on appetite sensations

    Randomized trialGilbert JA, Gasteyger C, Raben A, et al. Obesity (Silver Spring, Md.), 2012. PMID 21720440

  5. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial

    Randomized trialAstrup A, Madsbad S, Breum L, et al. Lancet (London, England), 2008. PMID 18950853

  6. Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine

    Randomized trialLehr T, Staab A, Trommeshauser D, et al. The AAPS journal, 2010. PMID 20077053

  7. Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons

    StudyPerez CI, Luis-Islas J, Lopez A, et al. PloS one, 2024. PMID 38656972

  8. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity

    ReviewBello NT, Zahner MR Current opinion in investigational drugs (London, England : 2000), 2009. PMID 19777399

Search used: ("Tesofensine"[tiab]). Run it on PubMed

Research links

Also in Metabolic